In ongoing litigation over the safety of its diabetes drug Actos (pioglitazone HCl), Takeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. announced today that in the case of Bertha Triana and Delores Cipriano v. Takeda, et al., No. A680556, the jury found in favor of Takeda. The trial began on March 10 in Nevada state court.

Takeda prevailed in four previous Actos trials, and this decision brings to five the number of cases in which Takeda has prevailed. It is challenging a sixth case. In that case, Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. regarding claims that Actos contributed to a patient’s bladder cancer, the jury in a federal district court in Louisiana found in favor of the plaintiffs and awarded $1.475 million in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly. The jury also awarded $6 billion in punitive damages from Takeda and $3 billion from co-defendant, Eli Lilly. Eli Lilly co-promoted Actos with Takeda from 1999 to 2006.  

Source: Takeda Pharmaceutical